{"page":{"totalFilteredElements":14},"studies":[{"active":true,"description":"Zanubrutinib (Brukinsa®) in Patients With Waldenström's Macroglobulinemia (WM), Chronic Lymphocytic Leukemia (CLL) and Marginal Zone Lymphoma (MZL) - a Prospective Multicenter Observational Cohort Study","eudractNumber":null,"id":10642,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05326308","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-09T11:00:27+01:00","shortTitle":"ARIADNE","therapeutical":false,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"

A First – in Human\nPhase I, non-randomized, open-label, multicenter dose escalation trial of BI\n764532 administered by repeated intravenous infusions in patients with Small\nCell Lung Carcinoma and other neuroendocrine neoplasms expressing DLL3

","eudractNumber":"2019-000729-31","id":6385,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[{"name":"DLL3 (Delta-like 3)","id":"mt_29"}],"nctNumber":"NCT04429087","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2021-10-14T10:40:17+02:00","shortTitle":"BI 1438-0001","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_8","name":"Advanced"},{"id":"tl_9","name":"Metastatic"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of \nBMS-986504 Monotherapy in Participants with Advanced or Metastatic Non-small Cell Lung \nCancer (NSCLC) with Homozygous MTAP Deletion After Progression on Prior Therapies","eudractNumber":"2024-519814-29","id":10710,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"ALK","id":"mt_11"},{"name":"RAF (rapidly accelerated fibrosarcoma)","id":"mt_222"},{"name":"BRAF","id":"mt_9"},{"name":"EGFR","id":"mt_1"},{"name":"HER2/neu","id":"mt_19"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"NTRK","id":"mt_81"},{"name":"RET (Rezeptor-Tyrosinkinase)","id":"mt_76"},{"name":"ROS-1 (c-ros oncogene 1, receptor tyrosine kinase)","id":"mt_12"}],"nctNumber":"NCT06855771","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-09-12T13:09:19+02:00","shortTitle":"BMS-CA240-0009","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"CESS-R-CESS Register","eudractNumber":null,"id":10263,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-11-19T10:06:04+01:00","shortTitle":"CESS Registry","therapeutical":false,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"A Modular Phase I/II Open-label Dose Escalation and Dose \nExpansion Study to Evaluate the Safety, Pharmacokinetics, \nPharmacodynamics, and Efficacy of AZD5492, a T cell-engaging \nAntibody Targeting CD20 in Subjects with Relapsed or Refractory \nB-Cell Malignancies (TITANium) ","eudractNumber":"2024-511099-34-00","id":10005,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT06542250","phase":{"id":"ph_5","name":"Phase I/II"},"recruitmentStart":"2025-01-14T15:09:54+01:00","shortTitle":"D9960C00001 TITANium","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"
Phase 1 study evaluating genetically modified autologous T cells expressing a T cell recepter recognizing a cancer/germline Antigen in patients with recurrent and/or refractory solid Tumors (ACTengine IMA203-101)

Target: PRAME
","eudractNumber":"2019-002370-31","id":5992,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"},{"name":"PRAME (Nuclear Receptor Transcriptional Regulator)","id":"mt_171"}],"nctNumber":"NCT03686124","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2020-08-13T10:58:11+02:00","shortTitle":"IMA203-101 (Immatics-PRAME)","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"BZKF-Studie
A Phase Ia/Ib First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of IMA401, a Bispecific T Cell Engaging Receptor Molecule (TCER®), in Patients with Recurrent and/or Refractory Solid Tumors
","eudractNumber":"2021-004326-30","id":7252,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"},{"id":"hau","name":"Hauttumoren"},{"id":"hau1","name":"Malignes Melanom"}],"mutations":[{"name":"HLA (Humane Leukozytenantigene)","id":"mt_174"},{"name":"MAGEA (Melanoma-associated Antigen)","id":"mt_245"},{"name":"MAGEA4","id":"mt_187"},{"name":"MAGEA8","id":"mt_188"}],"nctNumber":"NCT05359445","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2022-07-18T10:30:48+02:00","shortTitle":"IMA401-101","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
","eudractNumber":"2020-005843-21","id":7303,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD19","id":"mt_55"}],"nctNumber":"NCT05041309","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2023-02-16T13:40:47+01:00","shortTitle":"KT-US-982-5968","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]},{"active":true,"description":"A phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma","eudractNumber":"2023-510322-32","id":9816,"indications":[{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno3","name":"Kopf-Hals-Malignome"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-02T12:28:02+02:00","shortTitle":"MERUS MCLA-158-CL02","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"},{"id":"tl_9","name":"Metastatic"}]},{"active":true,"description":"A Phase I clinical trial to assess safety and tolerability of autologous ROR1 CAR-T cells in ROR1+ tumors","eudractNumber":"2024-512019-36","id":10837,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"ROR 1","id":"mt_288"}],"nctNumber":null,"phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2025-04-09T13:41:47+02:00","shortTitle":"NCT-Studie: LION 1","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]}]}